An ivermectin-atorvastatin combination impairs nuclear transport inhibiting dengue infection in vitro and in vivo (2023)

Peer-Reviewed Study · Palacios-Rápalo SN, Farfan-Morales CN, Cordero-Rivera CD, De Jesús-González LA, Reyes-Ruiz JM, Meraz-Ríos MA, et al. (7 authors) · December 15, 2023

Palacios-Rápalo SN et al., 2023-12-15: Mechanistic dengue study showing ivermectin blocks nuclear import of the dengue NS3 protein through the importin alpha/beta1 pathway, and that adding atorvastatin reduced dengue infection in cells and in mice.

we found that IVM and ATV treatments reduce the alteration of nuclear pore complex (NPC) proteins, and an IVM+ATV combination reduced DENV infection both in vitro and in vivo.

Palacios-Rápalo SN et al., 2023-12-15: Mechanistic dengue study showing ivermectin blocks nuclear import of the dengue NS3 protein through the importin alpha/beta1 pathway, and that adding atorvastatin reduced dengue infection in cells and in mice. Cell-line and animal (mouse) study, no human subjects; country not stated in the abstract. Ivermectin inhibits NS3 nuclear localization via importin alpha/beta1; the combination reduced DENV infection in vitro and in vivo. Authors declare no competing interests. This is the mechanism paper behind the dengue hypothesis; it does not establish human benefit, which IVE-53 tested and did not find at the clinical level.